Fig. 2From: Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro Graph showing the percentage of EpCAM positive viable cell in patients’ pleura exudate after 7 days incubation with control BiTE® vs solitomab. EpCAM (p = 2.09378E-06); MT201/P1 (p = 0.001724101) significant differenceBack to article page